Author: Yue, H.; Nowak, R. P.; Overwijn, D.; Payne, N. C.; Fischinger, S.; Atyeo, C.; Baden, L. R.; Nilles, E. J.; Karlson, E. W.; Yu, X. G.; Li, J. Z.; Alter, G.; Mazitschek, R.; Fischer, E. S.
Title: Rapid 'mix and read' assay for scalable detection of SARS-CoV-2 antibodies in patient plasma Cord-id: x81i5365 Document date: 2020_9_3
ID: x81i5365
Snippet: The human beta coronavirus SARS-CoV-2, causative virus of COVID-19, has infected more than 15 million people globally and continues to spread. Widespread, population level testing to detect active and past infections is critical to curb the COVID-19 pandemic. Antibody (serological) testing is the only option for detecting past infections outside the narrow window accessible to nucleic acid-based tests. However, currently available serological assays commonly lack scalability. Here, we describe t
Document: The human beta coronavirus SARS-CoV-2, causative virus of COVID-19, has infected more than 15 million people globally and continues to spread. Widespread, population level testing to detect active and past infections is critical to curb the COVID-19 pandemic. Antibody (serological) testing is the only option for detecting past infections outside the narrow window accessible to nucleic acid-based tests. However, currently available serological assays commonly lack scalability. Here, we describe the development of a rapid homogenous serological assay for the detection of antibodies to SARS-CoV-2 in patient plasma. We show that the fluorescence-based assay accurately detects seroconversion in COVID-19 patients from less than 1 microliter of plasma. Using a cohort of samples from COVID-19 infected or healthy individuals, we demonstrate detection with 100% sensitivity and specificity. This assay addresses an important need for a robust, low barrier to implementation, and scalable serological assay with complementary strengths to currently available serological platforms.
Search related documents:
Co phrase search for related documents- absence presence and accurate detection: 1, 2
- absence presence and acute disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- absence presence and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- absence presence and lod detection: 1
- absence presence and lod detection limit: 1
- absence presence and low background: 1, 2
- absence presence and low concentration: 1, 2, 3
- absence presence and low response: 1, 2
- absence presence and low signal: 1
- abundant nucleocapsid protein and accurate detection: 1
- abundant nucleocapsid protein and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8
- abundant nucleocapsid protein and low concentration: 1
- academic commercial and acute disease: 1, 2
- academic commercial and acute respiratory syndrome: 1, 2, 3, 4, 5
- acceptor donor and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7
Co phrase search for related documents, hyperlinks ordered by date